Androgen-independent Prostate Cancer The Clinical Problem of a Growing Pelvic Tumour

Hernes, Eivor; Fosså, Sophie D.; Skovlund, Eva

doi:10.1080/02841860310014624

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may be discussed whether the pattern of expression of EGFRs in our AIPC patients, all with local problems, is representative for AIPC patients in general. As we have previously indicated, the clinical course and survival of AIPC patients with local problems seem to differ from that of AIPC patients with symptomatic bone metastases (Hernes et al, 2000;Hernes et al, 2003).…”

Section: Discussionmentioning

confidence: 93%

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

et al. 2004

View full text Add to dashboard Cite

Novel palliative strategies for patients with androgen-independent prostate cancer (AIPC) include targeting the epidermal growth factor receptor (EGFR) family. The aim of the present study was to investigate intrapatient changes of EGFRs during the development of AIPC. In total, 106 symptomatic AIPC patients were identified in whom prostatic biopsies (adenocarcinoma) were available both before the start of androgen deprivation (PRTR biopsy) and after the development of AIPC (AIPC biopsy). All four known subgroups of the EGFR family were determined by immunohistochemistry (IHC): c-erbB-1 (EGFR), c-erbB-2 (HER2/neu), c-erbB-3 (HER3) and c-erbB-4 (HER4). Moderate to strong membrane-specific staining was recorded semiquantitatively (o10% vs X10% ¼ IHC stained tumour cells: 'negative' vs 'positive' staining). The medical records were reviewed for clinical variables. During the development of AIPC, intrapatient changes occurred in two opposite directions for each of the four EGFRs: negativity changed to positivity, and vice versa, statistically significant only for the increase of c-erbB-1 expression (P ¼ 0.001). The c-erbB-2 expression in the AIPC biopsy was associated with a significantly shorter survival from the time of the AIPC biopsy (P ¼ 0.029). Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer. Further research is needed to understand the function of EGFRs in this malignancy.

show abstract

Section: Discussionmentioning

confidence: 93%

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

et al. 2004

View full text Add to dashboard Cite

show abstract

“…However, several reports of radiotherapy for local treatment of hormone-refractory prostate cancers indicate that radiotherapy adds an independent benefit in local tumor control, may improve survival, and certainly should be considered in the case of locally symptomatic, androgenindependent pelvic tumors [17][18][19]. Unfortunately, for locally advanced disease treated with radiation (with or without androgen deprivation) in two large Radiation Therapy Oncology Group (RTOG) studies, by 8 years, 23% to 42% had clear evidence of local progression [20,21].…”

Section: The Case For Local Controlmentioning

confidence: 99%

Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?

Canby-Hagino

Swanson²,

Crawford³

et al. 2005

Curr Urol Rep

View full text Add to dashboard Cite

Data from well-designed, prospective clinical trials are lacking to support treatment of primary tumor in men diagnosed with metastatic prostate cancer. However, a growing body of evidence suggests that treatment of the primary tumor may enhance cancer control and survival in some men. This evidence is examined and recommendations are made for identifying patients with metastatic prostate cancer who may benefit from definitive treatment of the prostate tumor.

show abstract

Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?

Canby-Hagino

Swanson²,

Crawford³

et al. 2005

Curr prostate rep

View full text Add to dashboard Cite

Androgen-independent Prostate Cancer The Clinical Problem of a Growing Pelvic Tumour

Cited by 4 publications

References 20 publications

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?

Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?

Contact Info

Product

Resources

About